Ronald E. White

发表

Meeting Report: Metabolites in Safety Testing (MIST) Symposium—Safety Assessment of Human Metabolites: What’s REALLY Necessary to Ascertain Exposure Coverage in Safety Tests?

Abigail Jacobs, Hongying Gao, R. Obach, 2013, The AAPS Journal.

Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability.

Tongtong Liu, Yung-Hsiang Chen, Cheng Li, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Rapid determination of pharmacokinetic properties of new chemical entities: in vivo approaches.

Walter A. Korfmacher, K. Cox, Ronald E. White, 2002, Combinatorial chemistry & high throughput screening.

Pharmacokinetics of Drug Candidates

Ronald E. White, 2008 .

A high-throughput cell-based reporter gene system for measurement of CYP1A1 induction.

K. Cheng, Ronald E. White, Y. Lau, 2002, Journal of pharmacological and toxicological methods.

Isolation of circulating metabolites in drug discovery using high-performance liquid chromatography, and their identification by liquid chromatography coupled with tandem mass spectrometry and nuclear magnetic resonance spectroscopy

K. Cox, A. Nomeir, M. Bryant, 2002 .

Development of a high-throughput in vitro assay using a novel Caco-2/rat hepatocyte system for the prediction of oral plasma area under the concentration versus time curve (AUC) in rats.

Tongtong Liu, Ronald E. White, Cheng Li, 2006, Journal of pharmacological and toxicological methods.

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:

Weiying Yang, Zhuyan Guo, Andrea Hart, 2006, Journal of medicinal chemistry.

Whatever happened to cassette-dosing pharmacokinetics?

Ronald E White, Prasarn Manitpisitkul, Ronald E. White, 2004, Drug discovery today.

Radiolabeled mass-balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessary

C. Prakash, F. Tse, S. Surapaneni, 2013, Xenobiotica; the fate of foreign compounds in biological systems.

Quantitative PCR assay for cytochromes P450 2B and 3A induction in rat precision-cut liver slices: correlation study with induction in vivo.

R. Morrison, K. Cheng, Ronald E. White, 2005, Journal of pharmacological and toxicological methods.

Semi-automated determination of plasma stability of drug discovery compounds using liquid chromatography-tandem mass spectrometry.

Walter A. Korfmacher, K. Ng, Gangfeng Wang, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Role of Biotransformation in Drug Discovery

Ronald E. White, 2014 .

Application and interpretation of hPXR screening data: Validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers.

R. Morrison, K. Cheng, Richard A Morrison, 2008, Biochemical pharmacology.

Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes.

Yau Yi Lau, Elpida Sapidou, Xiaoming Cui, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Vicriviroc, A Novel CCR5 Inhibitor, is NOT A p-glycoprotein Substrate In Vitro

R. Morrison, Ronald E. White, Cheng Li, 2005, Retrovirology.

Progression of Drug Metabolism

Ronald E. White, 2011 .

Insights from a three-dimensional model into ligand binding to constitutive active receptor.

V. Madison, Li Xiao, Ronald E. White, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Meeting Report: Metabolites in Safety Testing (MIST) Symposium—Safety Assessment of Human Metabolites: What’s REALLY Necessary to Ascertain Exposure Coverage in Safety Tests?

R. Obach, A. Jacobs, B. Booth, 2013, The AAPS Journal.

The Importance of Full and Correct Prediction of Human Metabolites in Discovery and Preclinical Development

Ronald E. White, 2014 .

Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034

Walter A. Korfmacher, Ronald E. White, K. Cheng, 2007, Perspectives in medicinal chemistry.

Review of Drug Metabolism in Drug Discovery and Development

Ronald E. White, 2012 .

Use of Pre-Clinical In Vitro and In Vivo Pharmacokinetics for the Selection of a Potent Hepatitis C Virus Protease Inhibitor, Boceprevir, for Clinical Development

Samir K. Gupta, Tongtong Liu, Ronald E. White, 2009 .